TRANSLATE · TARGET
11Which intervention points are causally validated and trial-ready?
Cellular rescue, mouse rescue, pathway reversal, and one human response window are different evidence levels. None alone establishes a safe disease-modifying treatment, dose, developmental window, target engagement marker, or clinical benefit.
POPULATION / COMPARATOR
Who or what should be compared?
Multiple patient alleles and isogenic controls, independently replicated relevant models, dose and safety studies, and only then an ethics- and regulator-reviewed human protocol with defined eligibility and outcomes.
STUDY DESIGN
How could the question be tested?
Require convergent target validation across patient alleles, isogenic correction, orthogonal rescue, relevant cell states, pharmacology, in-vivo models where justified, exposure and safety, target engagement, reversibility, developmental timing, and trial-ready natural-history outcomes.
EVIDENCE GATE
What would support the proposed link?
the target rescues a predefined ASH1L-dependent phenotype in more than one relevant model without unacceptable toxicity, the effect is replicated independently, target engagement is measurable, and the human protocol has a credible safety, dosing, outcome, ethics, and regulatory path.
STOP RULE
What would weaken it?
benefit appears only in one assay or complete knockout, requires toxic exposure, lacks target engagement, fails independent replication, or is extrapolated directly from oncology compounds, animal behavior, or an uncontrolled human response.